1. Caccia C, Maj R, Calabresi M, et al. Safinamide from molecular targets to a new anti-Parkinson drug. Neurology 2006;67(Suppl 2): S18–23.
2. Schapira AH. Safinamide in the treatment of Parkinson’s disease. Expert Opin Pharmacother 2010;11:2261–8.
3. Stocchi F, Arnold G, Onofrj M, et al.; Safinamide Parkinson’s Study Group. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004;63:746–8.
4. Stocchi F, Borgohain R, Onofrj M, et al.; Study 015 Investigators. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients. Mov Disord 2012;27:106–12.
5. Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 2006;67(Suppl 2):S24–9.